69 related articles for article (PubMed ID: 17117417)
1. Novel microdeletion in the transforming growth factor beta type II receptor gene is associated with giant and large cell variants of nonsmall cell lung carcinoma.
Wang JC; Su CC; Xu JB; Chen LZ; Hu XH; Wang GY; Bao Y; Huang Q; Fu SB; Li P; Lu CQ; Zhang RM; Luo ZW
Genes Chromosomes Cancer; 2007 Feb; 46(2):192-201. PubMed ID: 17117417
[TBL] [Abstract][Full Text] [Related]
2. Defective expression of transforming growth factor beta type II receptor (TGFBR2) in the large cell variant of non-small cell lung carcinoma.
Xu JB; Bao Y; Liu X; Liu Y; Huang S; Wang JC
Lung Cancer; 2007 Oct; 58(1):36-43. PubMed ID: 17566598
[TBL] [Abstract][Full Text] [Related]
3. Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor beta resistant cells.
Biswas S; Trobridge P; Romero-Gallo J; Billheimer D; Myeroff LL; Willson JK; Markowitz SD; Grady WM
Genes Chromosomes Cancer; 2008 Feb; 47(2):95-106. PubMed ID: 17985359
[TBL] [Abstract][Full Text] [Related]
4. Microsatellite instability(MSI) in non-small cell lung cancer(NSCLC) is highly associated with transforming growth factor-beta type II receptor(TGF-beta RII) frameshift mutation.
Kim WS; Park C; Hong SK; Park BK; Kim HS; Park K
Anticancer Res; 2000; 20(3A):1499-502. PubMed ID: 10928062
[TBL] [Abstract][Full Text] [Related]
5. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
[TBL] [Abstract][Full Text] [Related]
6. A dominant negative mutation of transforming growth factor-beta receptor type II gene in microsatellite stable oesophageal carcinoma.
Tanaka S; Mori M; Mafune K; Ohno S; Sugimachi K
Br J Cancer; 2000 May; 82(9):1557-60. PubMed ID: 10789724
[TBL] [Abstract][Full Text] [Related]
7. Somatic alterations of the serine/threonine kinase LKB1 gene in squamous cell (SCC) and large cell (LCC) lung carcinoma.
Strazisar M; Mlakar V; Rott T; Glavac D
Cancer Invest; 2009 May; 27(4):407-16. PubMed ID: 19229701
[TBL] [Abstract][Full Text] [Related]
8. Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma.
Lynch MA; Nakashima R; Song H; DeGroff VL; Wang D; Enomoto T; Weghorst CM
Cancer Res; 1998 Oct; 58(19):4227-32. PubMed ID: 9766642
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation.
Muñoz NM; Upton M; Rojas A; Washington MK; Lin L; Chytil A; Sozmen EG; Madison BB; Pozzi A; Moon RT; Moses HL; Grady WM
Cancer Res; 2006 Oct; 66(20):9837-44. PubMed ID: 17047044
[TBL] [Abstract][Full Text] [Related]
10. TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity.
Finger EC; Turley RS; Dong M; How T; Fields TA; Blobe GC
Carcinogenesis; 2008 Mar; 29(3):528-35. PubMed ID: 18174241
[TBL] [Abstract][Full Text] [Related]
11. LKB1 mutation in large cell carcinoma of the lung.
Zhong D; Guo L; de Aguirre I; Liu X; Lamb N; Sun SY; Gal AA; Vertino PM; Zhou W
Lung Cancer; 2006 Sep; 53(3):285-94. PubMed ID: 16822578
[TBL] [Abstract][Full Text] [Related]
12. Heterozygous TGFBR2 mutations in Marfan syndrome.
Mizuguchi T; Collod-Beroud G; Akiyama T; Abifadel M; Harada N; Morisaki T; Allard D; Varret M; Claustres M; Morisaki H; Ihara M; Kinoshita A; Yoshiura K; Junien C; Kajii T; Jondeau G; Ohta T; Kishino T; Furukawa Y; Nakamura Y; Niikawa N; Boileau C; Matsumoto N
Nat Genet; 2004 Aug; 36(8):855-60. PubMed ID: 15235604
[TBL] [Abstract][Full Text] [Related]
13. Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers.
Hempen PM; Zhang L; Bansal RK; Iacobuzio-Donahue CA; Murphy KM; Maitra A; Vogelstein B; Whitehead RH; Markowitz SD; Willson JK; Yeo CJ; Hruban RH; Kern SE
Cancer Res; 2003 Mar; 63(5):994-9. PubMed ID: 12615714
[TBL] [Abstract][Full Text] [Related]
14. The 3' UTR IGF2R-A2/B2 variant is associated with increased tumor growth and advanced stages in non-small cell lung cancer.
Kotsinas A; Evangelou K; Sideridou M; Kotzamanis G; Constantinides C; Zavras AI; Douglass CW; Papavassiliou AG; Gorgoulis VG
Cancer Lett; 2008 Feb; 259(2):177-85. PubMed ID: 18037232
[TBL] [Abstract][Full Text] [Related]
15. Truncating mutations in the ACVR2 gene attenuates activin signaling in prostate cancer cells.
Rossi MR; Ionov Y; Bakin AV; Cowell JK
Cancer Genet Cytogenet; 2005 Dec; 163(2):123-9. PubMed ID: 16337854
[TBL] [Abstract][Full Text] [Related]
16. Characterization of novel transforming growth factor-beta type I receptors found in malignant pleural effusion tumor cells.
Chen KL; Liu WH; Yang YY; Leu SJ; Shih NY
BMC Mol Biol; 2007 Aug; 8():72. PubMed ID: 17705854
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.
Sutterlüty H; Mayer CE; Setinek U; Attems J; Ovtcharov S; Mikula M; Mikulits W; Micksche M; Berger W
Mol Cancer Res; 2007 May; 5(5):509-20. PubMed ID: 17510316
[TBL] [Abstract][Full Text] [Related]
18. Microsatellite unstable colorectal cancer cell lines with truncating TGFbetaRII mutations remain sensitive to endogenous TGFbeta.
Baker K; Raut P; Jass JR
J Pathol; 2007 Nov; 213(3):257-65. PubMed ID: 17893910
[TBL] [Abstract][Full Text] [Related]
19. A haplotype of TGFBR1 is predominantly found in non-small cell lung cancer patients displaying TGFBR1 allelic-specific expression.
Sun J; Lei Z; Liu RY; Lu Y; Zhuang Z; Jiang X; Qian Q; Liu Z; Zhao J; Zhang HT
Oncol Rep; 2011 Mar; 25(3):685-91. PubMed ID: 21225232
[TBL] [Abstract][Full Text] [Related]
20. Loss of imprinting of PEG1/MEST in lung cancer cell lines.
Nakanishi H; Suda T; Katoh M; Watanabe A; Igishi T; Kodani M; Matsumoto S; Nakamoto M; Shigeoka Y; Okabe T; Oshimura M; Shimizu E
Oncol Rep; 2004 Dec; 12(6):1273-8. PubMed ID: 15547750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
